CD8+ cutaneous T-cell lymphoma (CTCL) is a relatively rare subset of the non-Hodgkins lymphomas. Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL. Herein, we report on a patient whose CD8+ CTCL completely responded to treatment with bexarotene.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.21231 | DOI Listing |
Publication Analysis
Top Keywords
cd8+ cutaneous
8
cutaneous t-cell
8
t-cell lymphoma
8
cd8+ ctcl
8
cd8+
4
lymphoma treated
4
treated bexarotene
4
bexarotene case
4
case report
4
report review
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!